ORIGINAL ARTICLE |
|
Year : 2020 | Volume
: 33
| Issue : 4 | Page : 1131-1138 |
|
Nepafenac and bromfenac versus a placebo in minimizing the incidence of pseudophakic cystoid macular edema after phacoemulsification
Hoda M. K. ElSobky1, Hanan A. E Ahmed Madi2, Mohammed S. A. Aziz1
1 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt 2 Department of Ophthalmology, Ministry of Health, Dakahlia, Egypt
Correspondence Address:
Hanan A. E Ahmed Madi Academic, Degree (MBBCH), Adress Hay El-gamaa Street, Elmansoura city, Dakahlia Governorate Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/mmj.mmj_27_20
|
|
Objectives
This study aims to evaluate the effect of two types of topical NSAIDs, nepafenac and bromfenac, in comparison with a placebo on macular edema after phacoemulsification.
Background
Cystoid macular edema (CME) is the commonest cause of visual decline after phacoemulsification.
Design
A prospective comparative randomized Open-label clinical trial was performed.
Patients and methods
A total of 75 patients with senile cataract were included in the present study. Of them, 19 patients were assigned to receive nepafenac 0.3% eye drops, 19 received bromfenac 0.09% eye drops, and 37 received a placebo. The primary outcome measure included the change in the mean spectral-domain optical coherence tomography central subfield thickness at 1 day, 1 week, 1, 2 and 3 months after surgery. The secondary outcome measures included the total macular volume at 1 day, 1 week, 1, 2, 3 months postoperatively; the percentage of eyes in each group that developed CME; and the corrected visual acuity on 6 and 12 weeks after surgery.
Results
For all retinal thickness measurements, a significant increase in all three groups had been detected, starting from the first week postoperatively. Compared with the control regimen, add-on bromfenac or nepafenac resulted in statistically significant minimization of the changes in the following parameters: change in the macular volume and the central subfield thickness.
Conclusion
Topical NSAIDs therapy 2 days before surgery has an additive effect in minimizing the risk of pseudophakic CME. Bromfenac has statistically surpassed nepafenac in minimizing the incidence of CME after uneventful phacoemulsification.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|